Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) Correlates with the Lymph Node and Receptor Status in Breast Cancer and Reduces Survival
Manoj Pandey, Kumkum Jha, Mohan Kumar, Mridula Shukla and Vijay K. Shukla
World Journal of Surgical Medical and Radiation Oncology 2016, 5:2
X-linked inhibitor of apoptosis protein (XIAP), also known as MIHA/hILP/BIRC4 is a novel member of the inhibitors of apoptosis (IAP) family located on chromosome Xq25. XIAP has the most potent anti-apoptotic effect in cells and, is able to inhibit the effector caspases -3,-7 and -9. This case control study reports the mRNA and protein expression of XIAP, apoptosis and its effect on the survival in breast cancer.
Materials and Methods
XIAP expression was measured by immunohistochemistry, western Blotting and RT PCR method in 29 controls and 90 patients with breast cancer. Apoptosis was detected by using based on in situ labelling of the fragmented DNA (terminal deoxynucleotidyl transferase mediated UTP nick end-label (TUNEL)) staining.
XIAP protein expression was seen in 62.1% of controls and 86.7% of breast cancers, while mRNA expression was seen in 51.7% of controls and 87.8% of breast cancer. The differences were statistically significant. past history of abortion (p=0.002), metastasis (p=0.002) and oestrogen receptor (p=0.04) were found as independent and significant predictor for overall survival in breast cancer. XIAP negative patients had higher survival; however, the difference was not statistically significant.
XIAP is an important biomarker of breast cancer. Its expression significantly correlates with expression of hormone receptors, and prognosis is better in XIAP negative breast cancer.